A detailed history of Fifth Third Bancorp transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Fifth Third Bancorp holds 878 shares of DVAX stock, worth $11,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares
878
Previous 840 4.52%
Holding current value
$11,168
Previous $9,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$10.05 - $11.61 $381 - $441
38 Added 4.52%
878 $9,000
Q2 2024

Jul 22, 2024

BUY
$10.73 - $12.58 $3,079 - $3,610
287 Added 51.9%
840 $9,000
Q1 2024

Apr 23, 2024

SELL
$11.7 - $14.98 $117 - $149
-10 Reduced 1.78%
553 $6,000
Q4 2023

Jan 19, 2024

BUY
$13.09 - $14.98 $104 - $119
8 Added 1.44%
563 $7,000
Q2 2023

Jul 25, 2023

BUY
$9.85 - $13.17 $2,107 - $2,818
214 Added 62.76%
555 $7,000
Q1 2023

Apr 24, 2023

BUY
$9.44 - $11.88 $2,577 - $3,243
273 Added 401.47%
341 $3,000
Q4 2022

Jan 25, 2023

SELL
$10.27 - $13.29 $790 - $1,023
-77 Reduced 53.1%
68 $0
Q3 2022

Oct 25, 2022

BUY
$9.93 - $17.44 $764 - $1,342
77 Added 113.24%
145 $2,000
Q2 2022

Aug 04, 2022

BUY
$7.45 - $12.83 $506 - $872
68 New
68 $1,000
Q1 2022

Apr 19, 2022

SELL
$9.75 - $14.44 $447,232 - $662,362
-45,870 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$13.17 - $20.94 $604,107 - $960,517
45,870 New
45,870 $645,000
Q3 2021

Oct 15, 2021

SELL
$9.16 - $19.83 $2,290 - $4,957
-250 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$7.25 - $10.99 $725 - $1,099
-100 Reduced 28.57%
250 $2,000
Q1 2021

May 07, 2021

BUY
$4.57 - $11.18 $1,599 - $3,913
350 New
350 $3,000
Q2 2019

Aug 07, 2019

SELL
$3.65 - $7.89 $2,555 - $5,523
-700 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$7.08 - $12.09 $4,956 - $8,463
700 New
700 $5,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.61B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.